REVIEW article
Front. Cardiovasc. Med.
Sec. General Cardiovascular Medicine
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1572559
From mitochondria to heart: the role and challenges of Mitochondrial antiviral signaling protein in cardiovascular disease
Provisionally accepted
- 1Guizhou Medical University, Guiyang, China
- 2Department of Cardiovascular Medicine, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Mitochondrial Antiviral Signaling Protein (MAVS) is a pivotal adaptor protein in the innate immune response, mediating the activation of NF-κB and type I interferon signaling pathways during viral infections. As an integral component of the mitochondrial outer membrane, MAVS also plays criti-cal roles in the regulation of apoptosis, cellular metabolism, and the activation of inflammasomes, including NLRP3 and caspase family members. Emerging evidence indicates that MAVS is not only essential in antiviral defense but also contributes significantly to the pathogenesis of various diseas-es, notably cardiovascular diseases. In this review, we provide a comprehensive overview of the mo-lecular structure of MAVS and the regulatory mechanisms modulating its activity. We further high-light the involvement of MAVS in the development of cardiovascular diseases through its participation in innate immune signaling and mitochondrial dynamics. Particular attention is given to the regulation of MAVS by post-translational modifications—such as ubiquitination, methylation, and acetylation—as well as by microRNAs and other mitochondria-associated proteins. These insights aim to deepen the understanding of MAVS as a potential biomarker and therapeutic target, offering novel perspectives for the prevention, diagnosis, and immunotherapeutic intervention of cardiovascular diseases.
Keywords: Mitochondrial antiviral signaling protein (MAVS), Inflammation, Mitochondrial homeostasis, innate immunity, Cardiovascular Diseases
Received: 07 Feb 2025; Accepted: 24 Jul 2025.
Copyright: © 2025 Jiang, Huang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Runze Huang, Department of Cardiovascular Medicine, Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, Guizhou Province, China
Wei Li, Department of Cardiovascular Medicine, Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, Guizhou Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.